Jianping Liu1, Juan Xia2, Gaowu Yan3, Yongheng Zhang1, Jing Ge1, Lin Cao4. 1. Department of Cardiothoracic Surgery, Suining Central Hospital, Suining, Sichuan, China. 2. Department of Pathology, Suining Central Hospital, Suining, Sichuan, China. 3. Department of Radiology, Suining Central Hospital, Suining, Sichuan, China. 4. Department of Intensive Care Unit, Suining Central Hospital, Suining, Sichuan, China.
Abstract
Aim: This meta-analysis study aimed to compare the efficacy and safety of TEVAR versus OCSR for TBAD patients. Methods: We systematically searched PubMed, EmBase, and the Cochrane library to identify studies compared the effectiveness of TEVAR and OCSR in TBAD patients from the inception up to July 2019. The summary results were calculated using a random-effects model. Results: The electronic search identified 1,894 studies, and 18 studies with 9,664 TBAD patients were included. We noted patients received TEVAR were associated with a reduced risk of in-hospital mortality, acute renal failure, respiratory failure, and bleeding as compared with OCSR, whereas no significant differences between groups for the risk of stroke, myocardial infarction, paraplegia, mesenteric ischaemia/infarction, reinterventions, sepsis, and spinal cord ischaemia.Conclusions: The findings of this meta-analysis study suggested that TEVAR resulted in more short-term survival benefits. Moreover, the reduced risk of acute renal failure, respiratory failure and bleeding was detected in TEVAR group. The treatment effects of TEVAR versus OCSR on specific complications should be further verified by a study with high-level of evidence.Key messageComprehensive collected studies investigated the treatment effectiveness between TEVAR and OCSR for TBAD patientsTEVAR resulted in more survival benefits, in addition to lower risk of acute renal failure, respiratory failure and bleedingThe results of stratified analyses according to patients' characteristics were conducted.
Aim: This meta-analysis study aimed to compare the efficacy and safety of TEVAR versus OCSR for TBAD patients. Methods: We systematically searched PubMed, EmBase, and the Cochrane library to identify studies compared the effectiveness of TEVAR and OCSR in TBAD patients from the inception up to July 2019. The summary results were calculated using a random-effects model. Results: The electronic search identified 1,894 studies, and 18 studies with 9,664 TBAD patients were included. We noted patients received TEVAR were associated with a reduced risk of in-hospital mortality, acute renal failure, respiratory failure, and bleeding as compared with OCSR, whereas no significant differences between groups for the risk of stroke, myocardial infarction, paraplegia, mesenteric ischaemia/infarction, reinterventions, sepsis, and spinal cord ischaemia.Conclusions: The findings of this meta-analysis study suggested that TEVAR resulted in more short-term survival benefits. Moreover, the reduced risk of acute renal failure, respiratory failure and bleeding was detected in TEVAR group. The treatment effects of TEVAR versus OCSR on specific complications should be further verified by a study with high-level of evidence.Key messageComprehensive collected studies investigated the treatment effectiveness between TEVAR and OCSR for TBAD patientsTEVAR resulted in more survival benefits, in addition to lower risk of acute renal failure, respiratory failure and bleedingThe results of stratified analyses according to patients' characteristics were conducted.
Authors: Santi Trimarchi; Christoph A Nienaber; Vincenzo Rampoldi; Truls Myrmel; Toru Suzuki; Eduardo Bossone; Valerio Tolva; Michael G Deeb; Gilbert R Upchurch; Jeanna V Cooper; Jianming Fang; Eric M Isselbacher; Thoralf M Sundt; Kim A Eagle Journal: Circulation Date: 2006-07-04 Impact factor: 29.690
Authors: Thomas T Tsai; Rossella Fattori; Santi Trimarchi; Eric Isselbacher; Truls Myrmel; Arturo Evangelista; Stuart Hutchison; Udo Sechtem; Jeanna V Cooper; Dean E Smith; Linda Pape; James Froehlich; Arun Raghupathy; James L Januzzi; Kim A Eagle; Christoph A Nienaber Journal: Circulation Date: 2006-11-13 Impact factor: 29.690
Authors: Anthony L Estrera; Charles C Miller; Hazim J Safi; Jennifer S Goodrick; Arash Keyhani; Eyal E Porat; Paul E Achouh; Riad Meada; Ali Azizzadeh; Jayesh Dhareshwar; Adnan Allaham Journal: Circulation Date: 2006-07-04 Impact factor: 29.690
Authors: Himanshu J Patel; David M Williams; Gilbert R Upchurch; Narasimham L Dasika; G Michael Deeb Journal: J Vasc Surg Date: 2009-09-26 Impact factor: 4.268
Authors: Christian Mpody; Jerry Cui; Hamdy Awad; Sujatha Bhandary; Michael Essandoh; Ronald L Harter; Joseph D Tobias; Olubukola O Nafiu Journal: J Cardiothorac Vasc Anesth Date: 2020-12-02 Impact factor: 2.628